Cadrenal Therapeutics, Inc. Common Stock (CVKD) 10-Year Financial Performance & Capital Metrics

CVKD • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesNASH & Liver Diseases

AboutCadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.Show more

Revenue $0
EBITDA -$11M -43.6%
Net Income -$11M -27.5%
EPS (Diluted) -8.73 +9.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -140.78% +82.0%
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 1.3x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 8 (bottom 8%)
✗Shares diluted 40.5% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-89.08%

EPS CAGR

10Y-

5Y-

3Y-

TTM-10.01%

ROCE

10Y Avg-179.4%

5Y Avg-179.4%

3Y Avg-179.4%

Latest-144.87%

Peer Comparison

NASH & Liver Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MAZEMaze Therapeutics, Inc.	1.92B	39.81	511.70		31.18%	-33.24%	3.91%	0.14
GNFTGenfit S.A.	313.52M	6.27	209	134.56%	-14.12%	-31.42%	4.54%	0.90
GYREGyre Therapeutics, Inc.	741.77M	7.70	154	-6.78%	6.2%	4.84%		0.02
TVRDTvardi Therapeutics, Inc.	42.31M	4.51	-0.10	-65.96%	-317.54%	-63.46%
UNCYUnicycive Therapeutics, Inc.	134.75M	6.27	-1.12	-100%		-89.15%		0.10
GLTOGalecto, Inc.	38.32M	23.95	-1.29			-237.68%		0.00
IVAInventiva S.A.	1.17B	6.12	-1.73	-47.37%	-13.75%
AKBAAkebia Therapeutics, Inc.	355.59M	1.34	-4.06	-17.7%	-7.07%	-38.24%

Profit & Loss

	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0
Revenue Growth %	-	-	-
Cost of Goods Sold+	1.27K	0	0
COGS % of Revenue	-	-	-
Gross Profit+	-1.27K	0	0
Gross Margin %	-	-	-
Gross Profit Growth %	-	1%	-
Operating Expenses+	2.7M	7.63M	10.96M
OpEx % of Revenue	-	-	-
Selling, General & Admin	2.31M	3.55M	6.75M
SG&A % of Revenue	-	-	-
Research & Development	392.86K	4.08M	4.21M
R&D % of Revenue	-	-	-
Other Operating Expenses	0	1.98K	1.88K
Operating Income+	-2.7M	-7.63M	-10.96M
Operating Margin %	-	-	-
Operating Income Growth %	-	-1.83%	-0.44%
EBITDA+	-2.7M	-7.63M	-10.96M
EBITDA Margin %	-	-	-
EBITDA Growth %	-	-1.83%	-0.44%
D&A (Non-Cash Add-back)	1.27K	1.98K	1.88K
EBIT	-6.61M	-8.34M	-10.65M
Net Interest Income+	-107.11K	231.99K	309.25K
Interest Income	-	249.09K	309.25K
Interest Expense	107.11K	17.1K	0
Other Income/Expense	-4.01M	-724.24K	309.25K
Pretax Income+	-6.71M	-8.36M	-10.65M
Pretax Margin %	-	-	-
Income Tax+	0	0	0
Effective Tax Rate %	1%	1%	1%
Net Income+	-6.71M	-8.36M	-10.65M
Net Margin %	-	-	-
Net Income Growth %	-	-0.24%	-0.27%
Net Income (Continuing)	-6.71M	-8.36M	-10.65M
Discontinued Operations	0	0	0
Minority Interest	0	0	0
EPS (Diluted)+	-8.66	-9.63	-8.73
EPS Growth %	-	-0.11%	0.09%
EPS (Basic)	-8.66	-9.63	-8.73
Diluted Shares Outstanding	775.64K	868.18K	1.22M
Basic Shares Outstanding	775.64K	868.18K	1.22M
Dividend Payout Ratio	-	-	-

Balance Sheet

	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	727.6K	8.49M	10.11M
Cash & Short-Term Investments	32.59K	8.4M	10.02M
Cash Only	32.59K	8.4M	10.02M
Short-Term Investments	0	0	0
Accounts Receivable	0	0	38.15K
Days Sales Outstanding	-	-	-
Inventory	0	0	0
Days Inventory Outstanding	-	-	-
Other Current Assets	672.29K	0	14.45K
Total Non-Current Assets+	50.58K	27.08K	10.74K
Property, Plant & Equipment	44.59K	23.29K	6.94K
Fixed Asset Turnover	-	-	-
Goodwill	0	0	0
Intangible Assets	0	0	0
Long-Term Investments	0	0	0
Other Non-Current Assets	-526.01K	3.79K	3.79K
Total Assets+	778.17K	8.52M	10.12M
Asset Turnover	-	-	-
Asset Growth %	-	9.95%	0.19%
Total Current Liabilities+	1.33M	826.88K	2.68M
Accounts Payable	404.9K	167.32K	1.5M
Days Payables Outstanding	116.74K	-	-
Short-Term Debt	43.73K	0	0
Deferred Revenue (Current)	0	0	0
Other Current Liabilities	605.29K	596.13K	1.18M
Current Ratio	0.55x	10.27x	3.77x
Quick Ratio	0.55x	10.27x	3.77x
Cash Conversion Cycle	-	-	-
Total Non-Current Liabilities+	4.99M	0	0
Long-Term Debt	553.34K	0	0
Capital Lease Obligations	21.35K	0	0
Deferred Tax Liabilities	0	0	0
Other Non-Current Liabilities	4.42M	0	0
Total Liabilities	6.33M	826.88K	2.68M
Total Debt+	640.71K	21.35K	0
Net Debt	608.12K	-8.38M	-10.02M
Debt / Equity	-	0.00x	-
Debt / EBITDA	-	-	-
Net Debt / EBITDA	-	-	-
Interest Coverage	-25.22x	-446.34x	-
Total Equity+	-5.55M	7.69M	7.44M
Equity Growth %	-	2.39%	-0.03%
Book Value per Share	-7.16	8.86	6.10
Total Shareholders' Equity	-5.55M	7.69M	7.44M
Common Stock	8.19K	13.02K	1.78K
Retained Earnings	-6.71M	-15.07M	-25.72M
Treasury Stock	0	0	0
Accumulated OCI	0	0	0
Minority Interest	0	0	0

Cash Flow

	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.2M	-3.53M	-7.36M
Operating CF Margin %	-	-	-
Operating CF Growth %	-	-1.93%	-1.08%
Net Income	-6.71M	-8.36M	-10.65M
Depreciation & Amortization	1.27K	1.98K	1.88K
Stock-Based Compensation	0	710.38K	1.42M
Deferred Taxes	0	0	0
Other Non-Cash Items	4.9M	3.97M	-352
Working Capital Changes	607.74K	144.31K	1.87M
Change in Receivables	0	0	0
Change in Inventory	0	0	0
Change in Payables	404.9K	-237.58K	1.34M
Cash from Investing+	-2.28K	-3.25K	-6.54K
Capital Expenditures	0	-3.25K	-6.54K
CapEx % of Revenue	-	-	-
Acquisitions	-	-	-
Investments	-	-	-
Other Investing	0	0	0
Cash from Financing+	1.24M	11.9M	8.98M
Debt Issued (Net)	-	-	-
Equity Issued (Net)	-	-	-
Dividends Paid	0	0	0
Share Repurchases	-	-	-
Other Financing	0	250K	3.84M
Net Change in Cash	-	-	-
Free Cash Flow+	-1.2M	-3.53M	-7.36M
FCF Margin %	-	-	-
FCF Growth %	-	-1.93%	-1.08%
FCF per Share	-1.55	-4.07	-6.04
FCF Conversion (FCF/Net Income)	0.18x	0.42x	0.69x
Interest Paid	0	0	0
Taxes Paid	0	0	0

Key Ratios

Metric	2022	2023	2024
Return on Equity (ROE)	-	-780.59%	-140.78%
Debt / Equity	-	0.00x	-
Interest Coverage	-25.22x	-446.34x	-
FCF Conversion	0.18x	0.42x	0.69x

Frequently Asked Questions

Growth & Financials

Cadrenal Therapeutics, Inc. Common Stock (CVKD) grew revenue by 0.0% over the past year. Growth has been modest.

Cadrenal Therapeutics, Inc. Common Stock (CVKD) reported a net loss of $14.4M for fiscal year 2024.

Dividend & Returns

Cadrenal Therapeutics, Inc. Common Stock (CVKD) has a return on equity (ROE) of -140.8%. Negative ROE indicates the company is unprofitable.

Cadrenal Therapeutics, Inc. Common Stock (CVKD) had negative free cash flow of $11.8M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener